Journal
EUROPEAN UROLOGY FOCUS
Volume 7, Issue 6, Pages 1287-1291Publisher
ELSEVIER
DOI: 10.1016/j.euf.2020.07.001
Keywords
Biomarker; Castrate resistant; Cell-free DNA; Liquid biopsy; Prostate cancer; Abiraterone; Enzalutamide; Androgen receptor pathway; inhibitor
Categories
Funding
- Australian Government Research Training Program (RTP) Scholarship
- NHMRC Postgraduate Scholarship
- Monash University Postgraduate Publications Award
- National Health and Medical Research Council (NHMRC, Australia) [APP1155163]
- National Breast Cancer Foundation (Australia) Career Development Fellowship [ECF-17-001]
- NHMRC Practitioner Fellowship [APP1102604]
- Cancer Council Victoria Early Career Seed Grant
- NHMRC Project Grant [GNT1098647]
- Victorian Cancer Agency Clinical Research Fellowship [CRF14009]
- Astellas Investigator-Initiated Grant
Ask authors/readers for more resources
Measuring changes in total cell-free DNA levels in plasma can help predict how patients with metastatic prostate cancer will respond to different treatments. Higher levels or changes in cfDNA concentration may be associated with worse treatment outcomes, but in some cases, an increase in total cfDNA levels may correlate with better efficacy.
Total plasma cell-free DNA (cfDNA) levels were recently shown to be prognostic in two large phase III trials of taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC). However, whether cfDNA concentration is predictive of treatment outcomes with androgen receptor pathway inhibitors (ARPIs) is unknown. We quantified plasma cfDNA levels at baseline (n = 74) and 4 weeks on treatment (n = 56) in a prospective cohort of mCRPC patients treated with the ARPIs abiraterone acetate or enzalutamide. Elevated total cfDNA concentration (log10) at both baseline (hazard ratio [HR] 5.5, p < 0.001) and week 4 (HR 7.5, p < 0.001) was a significant negative prognostic factor for overall survival (OS), a finding maintained after adjustment for plasma circulating tumour DNA fraction. Unexpectedly, a rise in cfDNA concentration from baseline to week 4 was also associated with significantly improved OS (HR 0.14, p = 0.003). Conversely, patients with >29.8% decrease in cfDNA from baseline (optimal cutpoint) had significantly shorter median OS than the rest of the cohort (10.5 vs 25.7 mo, p = 0.03). Collectively, our findings point to the potential prognostic utility of quantifying cfDNA in mCRPC and in particular suggest that dynamic changes in total cfDNA levels may be a novel early predictive biomarker for therapeutic outcome in ARPI-treated patients. Patient summary: We measured the levels of total cell-free DNA (cfDNA) in the plasma of patients with metastatic prostate cancer prior to and 4 weeks after starting new hormonal drugs. We found that patients with higher levels of cfDNA or a higher proportion of tumour-derived DNA at baseline had worse outcomes on hormonal therapies. Similarly, higher levels of cfDNA at 4 weeks into therapy were also associated with worse outcomes. However, a rise in total cfDNA levels at 4 weeks compared with baseline was linked with better outcomes. Measuring changes in cfDNA concentration may be a useful and technically straightforward early way to predict how patients will respond to treatment in metastatic prostate cancer. (c) 2020 European Association of Urology. Published by Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available